Literature DB >> 21957314

Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus.

Jennifer D Watkins1, Juan Diaz-Rodriguez, Nagadenahalli B Siddappa, Davide Corti, Ruth M Ruprecht.   

Abstract

In R5-tropic clade C simian-human immunodeficiency viruses (SHIV-Cs), we identified a 3-asparagine (3N) deletion mutation in the V2 loop stem of gp120 as the major determinant of neutralization escape of the anti-CD4-binding site (anti-CD4-bs) neutralizing monoclonal antibody (nMAb) b12. However, the more potent anti-CD4-bs nMAbs VRC01 and VRC03 were not sensitive to this mutation. Using isogenic tier 1 or tier 2 proviruses differing only in the 3N mutation, we showed that this mutation might result in selective conformational b12 epitope masking. Therefore, human immunodeficiency virus (HIV) Env immunogens targeting the CD4-bs and designed to neutralize tier 2 viruses should take conformational masking by the V2 loop into account.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21957314      PMCID: PMC3209380          DOI: 10.1128/JVI.05994-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

3.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

4.  Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

Authors:  J R Mascola; M G Lewis; G Stiegler; D Harris; T C VanCott; D Hayes; M K Louder; C R Brown; C V Sapan; S S Frankel; Y Lu; M L Robb; H Katinger; D L Birx
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Authors:  P W Parren; P A Marx; A J Hessell; A Luckay; J Harouse; C Cheng-Mayer; J P Moore; D R Burton
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

9.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

10.  Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies.

Authors:  Flavia Ferrantelli; Robert A Rasmussen; Kathleen A Buckley; Pei-Lin Li; Tao Wang; David C Montefiori; Hermann Katinger; Gabriela Stiegler; Daniel C Anderson; Harold M McClure; Ruth M Ruprecht
Journal:  J Infect Dis       Date:  2004-05-26       Impact factor: 5.226

View more
  11 in total

1.  HIV-1 Nef responsiveness is determined by Env variable regions involved in trimer association and correlates with neutralization sensitivity.

Authors:  Yoshiko Usami; Heinrich Göttlinger
Journal:  Cell Rep       Date:  2013-10-24       Impact factor: 9.423

2.  N463 Glycosylation Site on V5 Loop of a Mutant gp120 Regulates the Sensitivity of HIV-1 to Neutralizing Monoclonal Antibodies VRC01/03.

Authors:  Wenbo Wang; Brett Zirkle; Jianhui Nie; Jian Ma; Kai Gao; Xiaojiang S Chen; Weijing Huang; Wei Kong; Youchun Wang
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

3.  Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5.

Authors:  Megan E Mefford; Kevin Kunstman; Steven M Wolinsky; Dana Gabuzda
Journal:  Virology       Date:  2015-03-20       Impact factor: 3.616

4.  Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope.

Authors:  Annette N Ratcliff; Colin M Venner; Abayomi S Olabode; Jason Knapp; Joshua Pankrac; Iulian Derecichei; Richard M Gibson; Andrés Finzi; Yue Li; Jamie F S Mann; Eric J Arts
Journal:  J Virol       Date:  2022-07-05       Impact factor: 6.549

5.  The selection of low envelope glycoprotein reactivity to soluble CD4 and cold during simian-human immunodeficiency virus infection of rhesus macaques.

Authors:  Kathleen McGee; Hillel Haim; Birgit Korioth-Schmitz; Nicole Espy; Hassan Javanbakht; Norman Letvin; Joseph Sodroski
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

6.  Association of MHC-I genotypes with disease progression in HIV/SIV infections.

Authors:  Takushi Nomura; Tetsuro Matano
Journal:  Front Microbiol       Date:  2012-06-29       Impact factor: 5.640

7.  Structural mechanism of trimeric HIV-1 envelope glycoprotein activation.

Authors:  Erin E H Tran; Mario J Borgnia; Oleg Kuybeda; David M Schauder; Alberto Bartesaghi; Gabriel A Frank; Guillermo Sapiro; Jacqueline L S Milne; Sriram Subramaniam
Journal:  PLoS Pathog       Date:  2012-07-12       Impact factor: 6.823

8.  A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.

Authors:  Aneesh Vijayan; Juan García-Arriaza; Suresh C Raman; José Javier Conesa; Francisco Javier Chichón; César Santiago; Carlos Óscar S Sorzano; José L Carrascosa; Mariano Esteban
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

9.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds.

Authors:  Tom L G M van den Kerkhof; Steven W de Taeye; Brigitte D Boeser-Nunnink; Dennis R Burton; Neeltje A Kootstra; Hanneke Schuitemaker; Rogier W Sanders; Marit J van Gils
Journal:  Retrovirology       Date:  2016-07-07       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.